Navigation Links
Celadrin(R) Research Unveiled at Nutrigenomics 2008 Meeting in Paris, France
Date:3/19/2008

-Demonstrates How Clinically Proven Celadrin(R) Achieves Its Results

SAN DIEGO, March 19 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today that Director of Research and Development, Dr. Robert Hesslink, presented basic research outlining the cellular pathway instrumental in the efficacy of Celadrin(R). Dr. Hesslink outlined the pathway before an audience of scientists and industry leaders at the Nutrigenomics 2008 meeting in Paris, France. The meeting was sponsored by the International Society of Antioxidant in Nutrition and Health and held at the prestigious Universite Paris V, Faculte de Medecine Paris Descartes.

The clinical efficacy of Celadrin(R) has been published in such esteemed journals as the Journal of Rheumatology and the Journal of Strength Conditioning and Research. It has been shown that Celadrin(R) reduces joint and muscular discomfort within 30 minutes of topical application and within 14 days of oral consumption.

In Paris, Dr. Hesslink presented research from radio tracer label data and ligand binding assays supporting the hypothesis that Celadrin(R) interacts with membrane receptors involved with the inflammatory cascade. To support this hypothesis, Dr. Hesslink presented dual-label tracer data from the laboratory of Dr. Daniel Gallaher at the University of Minnesota showing the appearance of the labeled components of Celadrin(R) in the phospholipid fractions. The greatest amount of the label was found in the phospholipid fractions of liver homogenates (e.g. microsomes) and white blood cell microsomes.

In addition, Dr. Hesslink presented in vitro and binding assay studies conducted by a world leading clinical discovery organization for the pharmaceutical and biotechnology industries. In these in vitro studies, Celadrin(R) was shown to inhibit the thromboxane synthase enzyme using prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2) as substrates. Thromboxane is a very strong facilitator of inflammation and local tissue damage through a variety of mechanisms. To further elucidate the mechanism of action on thromboxane production, receptor binding assays were carried out on the thromboxane A2 membrane receptor. Celadrin(R) was found to exert strong receptor binding inhibition using a standard radio binding assay.

"The appearance of labeled Celadrin(R) within cellular membranes, especially those of the white blood cells coupled with inhibition of thromboxane production or receptor inhibition suggests that Celadrin(R) influences the prostaglandin cascade and resulting inflammation," stated Dr. Hesslink. "It is this cellular data along with our safety and clinical efficacy data which provided the International Federation of Sports Medicine (FIMS) Executive Committee the confidence to select Celadrin(R) Topical Cream as FIMS' first and only Official Pain Relieving Cream."

Commenting on the presentation, Mr. William Spencer, Imagenetix's Chief Executive Officer said, "We have completed a number of clinical studies which have demonstrated the effectiveness of Celadrin(R) in both capsule and topical delivery methods. These additional studies were conducted to determine how these results are achieved. We are pleased at the reaction of scientists to this presentation and with the acceptance of Celadrin(R) within the international community. Our international distribution partners are experiencing increased sales as their consumers see the benefits of Celadrin(R). Dr. Hesslink and his team have put together an impressive portfolio of research documenting the safety and efficacy of Celadrin(R)."

About Imagenetix

Based in San Diego, California, Imagenetix, (OTCBB: IAGX) is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates private-labels propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(R)-Celadrin(R), which has been clinically tested to relieve osteoarthritis pain and significantly improve joint health. For more information on Celadrin(R), please visit, http://www.celadrin.com.

About ISANH

The aim of ISANH is to advance the practical applications of antioxidants, in all related fields, with particular reference to health and nutrition, and provide recommendations to ISANH's members, health decision makers and institutions about the last antioxidant trends, uses and problems. In addition, ISANH encourages communication and interaction among researchers, physicians, nutritionists, industrials, food technology and strategic marketing managers through a global antioxidants network, please visit http://www.isanh.com.

About FIMS

The Federation Internationale de Medecine du Sports (FIMS)/International Federation of Sports Medicine is an international organization comprised of individual members, national associations, and multinational groups, with a common involvement with sports medicine on all continents. FIMS aims primarily to promote the study and development of sports medicine throughout the world, to assist athletes in achieving optimal performance, and to enhance health through the practice of exercise and physical activity in the general population. http://www.fims.org.


'/>"/>
SOURCE Imagenetix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Research Confirms Better Oil from New DuPont High Oleic Soybean Trait
2. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
3. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
4. Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference
5. Professor Toh-Ming Lu named fellow of the Materials Research Society
6. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
7. BioMagnetics Diagnostics Corp. Rated Speculative Buy, Target Price $1.42 by Beacon Equity Research
8. Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
9. Cato Research Names John Cline as President
10. DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement
11. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 17, 2017 The Global Implantable Biomaterials ... of around 7.5% over the next decade to ... the prominent trends that the market is witnessing ... & graft transplant surgeries and medical implants and ... is categorized into immunomodulatory biomaterials, natural, polymers, hydrogels ...
(Date:1/17/2017)... Ind. , Jan. 17, 2017  Zimmer Biomet ... fourth quarter and full-year 2016 sales and earnings conference ... Tuesday, January 31, 2017, at 8 a.m. Eastern Time.  ... will be made available at 7:30 a.m. Eastern Time ... live audio webcast can be accessed via Zimmer Biomet,s ...
(Date:1/17/2017)... , Jan. 17, 2017 Research ... report "Molecular Diagnostics - Technologies, Markets and Companies" ... ... diagnostics has increased remarkably during the past few years. More ... developing molecular diagnostics and 342 of these are profiled in ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... 2016 annual meeting of the North American Spine Society (NASS)1 demonstrate high ... the majority of cases, when PEEK-OPTIMA™ HA Enhanced is used for interbody-fusion ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the addition ... offering. The report forecasts the global military biometrics market ... The report has been prepared based on an in-depth market ... and its growth prospects over the coming years. The report also includes ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
Breaking Biology News(10 mins):